AER 1523158 is a spontaneous case received on 16/Jan/2015 from physician via company sales representative 
and concerns a male patient of unspecified age who developed progressive multifocal leukoencephalopathy while 
being treated with rituximab (Mabthera).
Past drugs included dexamethasone, cytarabine and cisplatin were reported. No medical history, concurrent 
conditions, concomitant medications were reported.
On an unknown date, patient started therapy with intravenous rituximab (dose, form and frequency not reported) for
high-stage B-cell non-Hodgkin lymphoma. He received his last dose of rituximab before he underwent autograft in 
(b) (6) .  A few days after autograft, he experienced cognitive disorders and aphasia. Later, he underwent 
magnetic resonance imaging (MRI) which suggested a progressive multifocal leukoencephalopathy. His lumbar 
puncture evidence showed John Cunningham (JC) virus in his spinal fluid and he was hospitalized in the neurology 
department. It was reported that, since the diagnosis his disorders worsened.
Print Time: 26-MAY-2016 01:56 PM If a field is blank, there is no data for that field Page 388 of 675
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
At the time of report, outcome of event progressive multifocal leukoencephalopathy was persisting and therapy 
status of rituximab was unknown.
The reporter did not assessed causal relationship of event progressive multifocal leukoencephalopathy with 
rituximab.
The French rating concerning the event progressive multifocal leukoencephalopathy was C1 S2 I1 for rituximab.
Further information was requested.